Sequence information
Variant position: 334 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: 1040 The length of the canonical sequence.
Location on the sequence:
LLWAAGQDFQEFLFVFPFSC
R QLQCMAKPLSVRTLLFEHCC
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human LLWAAGQDFQEFLFVFPFSCR QLQCMAKPLSVRTLLFEHCC
Chimpanzee LLWAAGRDFQEFLFVFPFSCR QLQCMAKPLSVRTLLFEHCC
Mouse LLWATGRSFQEFLFIFPFSCR QLQCVAKPLSLRTLLFEHCC
Bovine LLWASGRAFQEFLFVFPFSCR QLQCLVKPLSMRTLLFEHCC
Sequence annotation in neighborhood: The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:Type: the type of sequence feature. Positions: endpoints of the sequence feature. Description: contains additional information about the feature.
Type Positions Description
Chain
1 – 1040
Nucleotide-binding oligomerization domain-containing protein 2
Domain
293 – 618
NACHT
Alternative sequence
225 – 1040
Missing. In isoform 3.
Literature citations
Interaction between NOD2 and CARD9 involves the NOD2 NACHT and the linker region between the NOD2 CARDs and NACHT domain.
Parkhouse R.; Boyle J.P.; Mayle S.; Sawmynaden K.; Rittinger K.; Monie T.P.;
FEBS Lett. 588:2830-2836(2014)
Cited for: INTERACTION WITH CARD9; VARIANTS IBD1 ALA-357; PHE-363 AND VAL-550; VARIANT ALA-463; CHARACTERIZATION OF VARIANTS IBD1 ARG-248; ALA-357; PHE-363; LEU-431; LYS-441; VAL-550; VAL-612 AND TRP-702; CHARACTERIZATION OF VARIANT BLAUS TRP-334; CHARACTERIZATION OF VARIANT ALA-463; MUTAGENESIS OF ASP-379;
Blau syndrome polymorphisms in NOD2 identify nucleotide hydrolysis and helical domain 1 as signalling regulators.
Parkhouse R.; Boyle J.P.; Monie T.P.;
FEBS Lett. 588:3382-3389(2014)
Cited for: SUBCELLULAR LOCATION; CHARACTERIZATION OF VARIANTS BLAUS GLN-334; TRP-334; GLY-383; LYS-383; PHE-469; ASP-481; LEU-490; TYR-495; LEU-496; THR-513; CYS-587; ASN-605; PRO-605 AND LYS-670; CHARACTERIZATION OF VARIANTS AND CYS-471;
CARD15 mutations in Blau syndrome.
Miceli-Richard C.; Lesage S.; Rybojad M.; Prieur A.M.; Manouvrier-Hanu S.; Hafner R.; Chamaillard M.; Zouali H.; Thomas G.; Hugot J.-P.;
Nat. Genet. 29:19-20(2001)
Cited for: VARIANTS BLAUS GLN-334; TRP-334 AND PHE-469;
Early-onset sarcoidosis and CARD15 mutations with constitutive nuclear factor-kappaB activation: common genetic etiology with Blau syndrome.
Kanazawa N.; Okafuji I.; Kambe N.; Nishikomori R.; Nakata-Hizume M.; Nagai S.; Fuji A.; Yuasa T.; Manki A.; Sakurai Y.; Nakajima M.; Kobayashi H.; Fujiwara I.; Tsutsumi H.; Utani A.; Nishigori C.; Heike T.; Nakahata T.; Miyachi Y.;
Blood 105:1195-1197(2005)
Cited for: VARIANTS BLAUS TRP-334; GLU-382; LEU-496; THR-513; PRO-605; THR-612 AND LYS-670; CHARACTERIZATION OF VARIANTS BLAUS GLU-382; LEU-496; THR-513; PRO-605 AND LYS-670;
NOD2-associated pediatric granulomatous arthritis, an expanding phenotype: study of an international registry and a national cohort in Spain.
Rose C.D.; Arostegui J.I.; Martin T.M.; Espada G.; Scalzi L.; Yague J.; Rosenbaum J.T.; Modesto C.; Cristina Arnal M.; Merino R.; Garcia-Consuegra J.; Carballo Silva M.A.; Wouters C.H.;
Arthritis Rheum. 60:1797-1803(2009)
Cited for: VARIANTS BLAUS GLN-334; TRP-334; LYS-383; LEU-490; TYR-495 AND CYS-587;
Role of the NOD2 genotype in the clinical phenotype of Blau syndrome and early-onset sarcoidosis.
Okafuji I.; Nishikomori R.; Kanazawa N.; Kambe N.; Fujisawa A.; Yamazaki S.; Saito M.; Yoshioka T.; Kawai T.; Sakai H.; Tanizaki H.; Heike T.; Miyachi Y.; Nakahata T.;
Arthritis Rheum. 60:242-250(2009)
Cited for: VARIANTS BLAUS GLN-334; TRP-334; GLU-382; GLY-383; TYR-495; LEU-496; THR-513; PRO-605 AND LYS-670;
Sporadic Blau syndrome with onset of widespread granulomatous dermatitis in the newborn period.
Stoevesandt J.; Morbach H.; Martin T.M.; Zierhut M.; Girschick H.; Hamm H.;
Pediatr. Dermatol. 27:69-73(2010)
Cited for: VARIANT BLAUS TRP-334;
Disclaimer:
Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.